Key result
First treatment with surgery linked to ~92% lower mortality vs best supportive care in angiosarcoma.
Why the study?
Angiosarcoma is rare with poor 5-year survival, and limited large cohort data are available to identify modifiable predictors of survival.
Does active treatment (surgery, radiation, or chemotherapy) improve survival in patients with angiosarcoma compared to supportive care alone?
Cohort (n=145)
No
Does active treatment (surgery, radiation, or chemotherapy) improve survival in patients with angiosarcoma compared to supportive care alone?
Hazard Ratio: 0.08
p-value: p=<0.01
In patients with angiosarcoma, active treatment with surgery, radiation, or chemotherapy significantly improves overall survival compared to supportive care alone, with complete surgical resection offering the greatest benefit.
Surgery was associated with markedly longer survival than supportive care in angiosarcoma; leaves open benefit of radiation or chemotherapy and requires prospective confirmation.
Angiosarcoma is a subset of soft-tissue sarcomas with poor 5-year survival rate. Given its rarity, limited large cohort data is available for this disease. Therefore, the present study evaluated data from patients with angiosarcoma treated at a provincial Institution (BC Cancer) to determine potential modifiable predictors of survival. A retrospective review of patients across British Columbia (Canada) was conducted at the Sarcoma Outcome Unit of BC Cancer from January 1, 1969 to September 19, 2017. Cox proportional hazard models were used to calculate hazard ratios (HR) for the overall survival (OS) and progression free survival (PFS) of patients. A total of 145 patients with angiosarcoma were identified, of which 68 were metastatic/unresectable at presentation. Of the 145 patients included, 38 received chemotherapy, with 15 receiving taxane. A single patient received chemotherapy in a neoadjuvant setting. Of the resectable patients, 71 had first line surgery and 38 had curative-intent radiation during their treatment. Of the study cohort, 38 patients received prior radiation for an unrelated cancer and 4 patients had pre-existing chronic lymphedema. Resectable disease (HR, 0.22; P<0.01), first treatment with either surgery (HR, 0.08; P<0.01), radiation (HR, 0.19; P<0.01) or chemotherapy (HR, 0.22; P<0.01) were predictors of improved OS. First line surgery resulted in improved OS (HR, 0.36; P<0.01) and PFS (HR, 0.48; P<0.01). In addition, OS was positively impacted by the extent of surgery [complete (R0) vs. microscopic residual tumor (R1); HR, 0.26; P<0.01; R0 vs. macroscopic residual tumor (R2); HR, 0.08; P<0.01) resection. Extent of surgery and any radiation treatment were determined to be important predictors of OS. The results also revealed that patient outcome was improved following any treatment compared with supportive care alone. In conclusion, multidisciplinary care is critical for the treatment of patients diagnosed with angiosarcoma.
No takes yet. Share an insight, caveat, or question.
Smrke et al. (2020) conducted a cohort in Angiosarcoma (n=145). First treatment with surgery vs. Best supportive care was evaluated on Overall survival (HR 0.08, p=<0.01). First treatment with surgery significantly improved overall survival compared to best supportive care in patients with angiosarcoma (HR 0.08).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: